NPM1 and acute myeloid leukemia: It may be speculated that the relatively favorable outcomes observed in patients suffering from the highly immunogenic NPM1-mutated AML and receiving this frontline therapeutic regimen could be, at least in part, the result of immune-mediated mechanisms.